XML 27 R17.htm IDEA: XBRL DOCUMENT

SEGMENTED INFORMATION

9 Months Ended

Sep. 30, 2022

NOTE 11 - SEGMENTED INFORMATION

At September 30, 2022, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

	BioNexus Gene Lab Corp., a Wyoming company

100% owned		100% owned
Bionexus Gene Lab Sdn. Bhd., a Malaysian company		Chemrex Corporation Sdn. Bhd., a Malaysian company

At September 30, 2022, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

For the quarter ended September 30, 2022, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

	BioNexus Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2022

REVENUE	$	39,409		$	8,049,723		$	-		$	8,089,132

COST OF REVENUE		(19,173	)		(7,150,156	)		-			(7,169,329	)

GROSS (LOSS)/PROFIT		20,236			899,567			-			919,803

OTHER INCOME		6,617			146,720			3			153,340

OPERATING EXPENSES
General and administrative		(157,686	)		(906,698	)		(177,247	)		(1,241,631	)

FINANCE COSTS		(2,196	)		(5,521	)		-			(7,717	)

(LOSS)/PROFIT BEFORE TAX		(133,029	)		134,068			(177,244	)		(176,205	)

Tax expense		-			(22,792	)		-			(22,792	)

NET (LOSS)/PROFIT	$	(133,029	)	$	111,276		$	(177,244	)	$	(198,997	)

	BioNexus Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2021
REVENUE	$	1,504,064		$	8,613,232		$	-		$	10,117,296

COST OF REVENUE		(1,057,314	)		(7,270,208	)		-			(8,327,522	)

GROSS PROFIT		446,750			1,343,024			-			1,789,774

OTHER INCOME		5,335			154,429			-			159,764

OPERATING EXPENSES
General and administrative		(115,758	)		(843,620	)		(135,396	)		(1,094,774	)

FINANCE COSTS		(3,265	)		(5,722	)		-			(8,987	)

PROFIT/(LOSS) BEFORE TAX		333,062			648,111			(135,396	)		845,777

Tax expense		(38,068	)		(145,381	)		-			(183,449	)

NET PROFIT/(LOSS)	$	294,994		$	502,730		$	(135,396	)	$	662,328

	As of September 30, 2022 and December 31, 2021
	Total Assets				Total Liabilities
	2022		2021		2022		2021

BGLC & Bionexus	$	870,929	$	1,167,214	$	64,914	$	121,586
Chemrex		6,927,307		8,407,176		1,309,668		2,273,025
TOTAL		7,798,236		9,574,390		1,374,582		2,394,611